Dual drug delivery using "smart" liposomes for triggered release of anticancer agents

Journal of Nanoparticle Research

Volumn 15, Issue 7, 2013, Pages

  Jain, Ankit ^a   Gulbake, Arvind ^a   Jain, Ashish ^a   Shilpi, Satish ^a   Hurkat, Pooja ^a   Jain, Sanjay K ^a  

^a DR H S GOUR UNIVERSITY   (India)

Author keywords

Folate receptor; Liposomes; Ovarian cancer; Paclitaxel; Topotecan

Indexed keywords

CELL CULTURE; CONTROLLED DRUG DELIVERY; DISEASES; DRUG PRODUCTS; LIPOSOMES; TUMORS;

ANTI-CANCER AGENTS; CYTOTOXICITY ASSAYS; FOLATE RECEPTOR; GYNECOLOGIC CANCER; OVARIAN CANCERS; PACLITAXEL; PEGYLATED LIPOSOMES; TOPOTECAN;

TARGETED DRUG DELIVERY;

FOLATE RECEPTOR 1; LIPOSOME; PACLITAXEL; TOPOTECAN;

ARTICLE; CANCER CELL CULTURE; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; FLUORESCENCE MICROSCOPY; GENE OVEREXPRESSION; HEAT SENSITIVITY; IN VITRO STUDY; LIPID COMPOSITION; LIPID VESICLE; PARTICLE SIZE; PH; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE; TUMOR MICROENVIRONMENT;

EID: 84878895105     PISSN: 13880764     EISSN: 1572896X     Source Type: Journal    
DOI: 10.1007/s11051-013-1772-5     Document Type: Article

References (37)

1. Bokkel H, Lane GA (2004) Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Ann Oncol 15:100-103 (Pubitemid 38139610)
2. Burke TG, Gao X (1994) Stabilization of TPT in low pH liposomes composed of distearoylphosphatidyl-choline. J Pharm Sci 83:967-969 (Pubitemid 24228546)
3. Crosasso P, Ceruti M, Brusa P, Arpicco S, Cattel L (2000) Preparation, characterization and properties of sterically stabilized paclitaxel containing liposomes. J Control Release 63:19-30 (Pubitemid 30046939)
4. Dadashzadeh S, Vali AM, Rezaie M (2008) The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats. Int J Pharm 353:251-259
5. Danhier F, Feron O, Preat V (2010) To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release 148:135-146
6. Frederick GV et al (2006) A study of variable hydration states in topotecan hydrochloride. J Pharm Biomed Anal 40:1080-1088 (Pubitemid 43247444)
7. Fry DW, White JC, Goldman ID (1978) Rapid separation of low molecular weight solutes from liposomes without dilution. Anal Biochem 90(2):809-815 (Pubitemid 9087732)
8. Gore M et al (2001) Clinical evidence for topotecan-paclitaxel non-cross-resistance in ovarian cancer. J Clin Oncol 19:1893-1900 (Pubitemid 32702532)
9. Guo J, Ping Q, Sun G, Jiao C (2000) Lecithin vesicular carriers for transdermal delivery of cyclosporin. Int J Pharma 194:201-207 (Pubitemid 30110682)
10. Gupta Y, Soni V, Chourasia MK, Jain A, Khare P (2005) Targeted drug delivery to the brain via transferrin coupled liposomes. Drug Deliv Tech 5:66-71
11. Homesley H, Benigno B, Williams J, Vaccarello L (2002) A phase I study of weekly topotecan and paclitaxel in previously treated epithelial ovarian carcinoma patients. Gynecol Oncol 87:171-177 (Pubitemid 36044082)
12. Huinink WB, Lane SR, Ross GA (2004) Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Ann Oncol 15:100-103 (Pubitemid 38139610)
13. Immordino ML, Dosio F, Cattel L (2006) Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine 1(3):297-315
14. Jemal A et al (2008) Cancer statistics. CA Cancer J Clin 58:71-96 (Pubitemid 351521864)
15. Kanwaldeep KG, Sami N, Amal K (2011) Paclitaxel loaded PEG5000-DSPE micelles as pulmonary delivery platform: formulation characterization, tissue distribution, plasma pharmacokinetics, and toxicological evaluation. Eur J Pharm Biopharm 79:276-284
16. Kastantin M, Ananthanarayanan B, Karmali P, Ruoslahti E, Tirrell M (2009) Effect of the lipid chain melting transition on the stability of DSPE-PEG (2000) micelles. Langmuir 25:7279-7286
17. Kaye S, Brown R, Gabra H (2011) Emerging therapeutic targets in ovarian cancer. Springer, New York
18. Kono K, Yoshino K, Takagishi T (2002) Effect of poly(ethylene glycol) grafts on temperature-sensitivity of thermosensitive polymer-modified liposomes. J Control Release 80:321-332 (Pubitemid 34273769)
19. Kudelka AP (1996) Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 14:1552-1557 (Pubitemid 26134213)
20. Lasic DD, Papahadjopoulos D (1998) Medical applications of liposomes. Elsevier, Amsterdam
21. Lee RJ, Low PS (1995) Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim Biophys Acta 1233:136
22. 31P-NMR. Langmuir 27:10041-10049
23. Oyewumi MO, Mumper RJ (2002) Engineering tumor-targeted gadolinium hexanedione nanoparticles for potential application in neutron capture therapy. Bioconjug Chem 13:1328-1335 (Pubitemid 35420027)
24. Pei K, Chih T, Wang A, Wu-Chou S (2011) A liposomal formulation able to incorporate a high content of paclitaxel and exert promising anticancer effect. J Drug Deliv. doi: 10.1155/2011/629234
25. Sharma A, Straubinger RM, Ojima I, Bernacki RJ (1995) Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice. J Pharm Sci 84:1400-1404
26. Skehn P et al (1990) New colorimetric cytotoxicity assay for anticancer drug screening. Natl Cancer Inst 82:1107
27. Smet M, Langereis S, Bosch SVD, Grul H (2010) Temperature-sensitive liposomes for doxorubicin delivery under MRI guidance. J Control Release 143:120-127
28. Straubinger RM, Sharma A, Murray M, Mayhew E (1993) Novel taxol formulations: taxol-containing liposomes. J Natl Cancer Inst Monogr 15:69-78
29. Tagami T, Ernsting MJ, Li S (2011) Optimization of a novel and improved thermosensitive liposome formulated with DPPC and a Brij surfactant using a robust in vitro system. J Control Release 154:290-297
30. Vichai V, Kirtikara K (2006) Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 1:1112-1116
31. Weinstein JN, Magin RL, Cysyk RL, Zaharko DS (1980) Treatment of solid L1210 murine tumors with local hyperthermia and temperature-sensitive liposomes containing methotrexate. Cancer Res 40:1388-1395 (Pubitemid 10101973)
32. Weissig V (2010) Liposomes-methods and protocols, Vol. 1: Pharmaceutical Nanocarriers, Springer Protocols., Methods in molecular biologySpringer, London
33. Weitman SD, Lark RH, Coney LR (1992) Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res 52:3396-3401
34. Woo J et al (2008) Use of a passive equilibration methodology to encapsulate cisplatin into preformed thermosensitive liposomes. Int J Pharm 349:38-46
35. Wu J, Liu Q, Lee RJ (2006) A folate receptor-targeted liposomal formulation for paclitaxel. Int J Pharm 316:148-153 (Pubitemid 43786219)
36. Yallapu MM, Jaggi M, Chauhan SC (2010) Scope of nanotechnology in ovarian cancer therapeutics. J Ovarian Res 3:19-29
37. Yang T et al (2007) Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation. Int J Pharm 338:317-326 (Pubitemid 46777245)